The patent details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2 (types of protein).
HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.
Together they form a novel receptor complex that represents a prognostic marker for HER2 positive breast cancer.
Zelda’s managing director Dr Richard Hopkins said: “We’re delighted with the allowance of this patent, which supports Zelda’s strategy of building a world-class intellectual property portfolio and the development of cannabis-based products.
“Further news is expected as this patent family progresses through the international examination phase.
“I’d also like to acknowledge the work of Professor Cristina Sanchez and her team who generated the data that supported this patent.
“This work was recently published in the prestigious peer-reviewed Proceedings of the National Academy of Sciences.
“This outcome highlights the benefit of Zelda’s approach of partnering with world-leading cannabis researchers.
“Importantly, Professor Sanchez’s discovery of a novel prognostic biomarker, will complement our ongoing efforts develop to cannabis-based medicines to treat breast cancer.”
A vertically integrated medical cannabis strategy
The company’s focus remains on the development of novel cannabinoid-based therapies for a range of diseases.
Zelda is undertaking a human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the US.
Pre-clinical research activities include programs examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.